Different kingdoms, not different brands. Lion’s mane is a shaggy white fungus fruiting on hardwood, its structure built on a chitinous cell wall, and the compound families named in the literature are hericenones from the fruiting body and erinacines from the mycelium. Ashwagandha is a farmed nightshade shrub, and the commercial part is the root, whose markers are steroidal lactones called withanolides. Placing them on a single scale is a category error, so what follows sets out what each has separately been measured for.
With lion’s mane the familiar question applies: fruiting body, or mycelium raised on a grain substrate. Grain brings starch, starch is an alpha-glucan, and alpha-glucan is counted inside any total polysaccharide figure. The Endoca Lion’s Mane Mushroom Gummies describe a water-based extract standardised to 50 percent polysaccharides, which is a polysaccharide figure rather than a beta-glucan figure.
With ashwagandha the question is whether any withanolide is present at all. When nine marketed Withania somnifera formulations were assayed by chromatography, total withanolide content varied widely between them, which is why the percentage matters more than the milligram figure beside it.
The beta-glucan figure belongs to the fungus alone, and even there it is inferred rather than measured directly. Total glucan is released by sulfuric acid hydrolysis and read as glucose; alpha-glucan is quantified separately once glucoamylase has digested starch and glycogen; beta-glucan is the remainder. A mycelium-on-grain powder consequently reports a generous total glucan with very little fungal glucan underneath it.
Two accepted assays also disagree with one another. The enzymatic route counts the glucose released, while the Congo red assay responds to the intact triple helix, and reviews of mushroom glucans state plainly that two values compare only when a single method produced both of them.
Ashwagandha has no counterpart figure, because no fungal cell wall exists in a root. Its analogue is withanolide content, and the same trap reappears in another form: solvent decides yield. In method development on Withania somnifera roots, aqueous alcohol mixtures returned the highest total withanolide content, so a water-only root powder and a hydroalcoholic root extract at the same stated weight are not the same material. Neither figure crosses over between the two.
Ashwagandha has the bigger trial count and the shakier internal agreement: heterogeneity of 98 percent in the anxiety analysis means the component trials very nearly contradicted each other. Lion’s mane rests on fewer studies, one positive only while the tablets continued.
Begin with who should avoid ashwagandha outright, because the list is long: anyone pregnant or breastfeeding, anyone under 18, anyone with liver disease, a thyroid disorder or a heart condition, and anyone taking central nervous system depressants. Where any of those apply the comparison is over, and lion’s mane is the only one of the pair left standing. For lion’s mane, check whether the label states fruiting body or mycelium, and read a polysaccharide percentage as the larger of the two possible numbers unless a separate beta-glucan figure is given alongside it.
Nothing about an effect on the body. Both are sold as food supplements, and no health claim for either has been authorised under Regulation (EC) No 1924/2006 as retained in Great Britain law. Reporting a trial result as a measured outcome is permissible; wording it as something the ingredient does for a reader is not.
Composition may be stated: species, part used, extraction solvent, milligrams per serving and batch analysis. A withanolide percentage and a beta-glucan percentage are both legitimate statements of content.
The ashwagandha liver signal is documented and is the most important item on this page. The first published series reported 5 patients, 3 collected in Iceland and 2 from the United States Drug-Induced Liver Injury Network; all became jaundiced after 2 to 12 weeks, injury was cholestatic or mixed, and itching with raised bilirubin lasted 5 to 20 weeks. A review to December 2025 covered 25 patients: 80 percent recovered, one needed a transplant and three died, all three with pre-existing cirrhosis. Ashwagandha is contraindicated in pregnancy.
Ashwagandha remains legal to sell here, but is under active review. The Food Standards Agency ran a call for evidence that closed on 2 September 2024 to support a Committee on Toxicity risk assessment, having named possible thyroid toxicity, hypoglycaemic effects and potential liver toxicity. Denmark prohibited it in food supplements in 2023 after a 2020 assessment found no safe intake level. Sweden has not prohibited it, though its food agency has required companies to demonstrate that ashwagandha products are safe. Lion’s mane has no comparable signal but is untested in pregnancy.
Endoca stocks lion’s mane and not ashwagandha, so only one of the two has a batch record here. The Lion’s Mane Mushroom Gummies carry 100 mg of organic Hericium erinaceus extract per serving across 15 servings, and the Lion’s Mane Mushroom Extract capsules hold 350 mg each. Batches are tested by a third-party laboratory with the certificate of analysis published through the lab portal. The gummy label reports polysaccharides rather than beta-glucan. Endoca has worked from its own farm, own land and own extraction since 2010.
They are not alternatives. Lion’s mane is a fungus studied for cognitive scales and reaction speed; ashwagandha is a nightshade root studied for anxiety and sleep. No trial has compared them, and only one of the two carries a documented liver injury signal.
Denmark barred it from food supplements in 2023, following a 2020 national risk assessment which found no intake level of the root or root extracts below which consumption would be free of risk. Sweden has not prohibited it, but its food agency has required companies to show that ashwagandha products are safe.
No, it is contraindicated. Germany’s risk institute advises that anyone pregnant or breastfeeding should not take it, France’s food safety agency gives the same advice, and reports have raised the possibility of spontaneous abortion. Lion’s mane has not been studied in pregnancy either.
It is thin. A double-blind trial randomised 30 adults with mild cognitive impairment into two groups of 15; scores rose at weeks 8, 12 and 16 and then fell 4 weeks after stopping. A systematic review located five randomised trials, none running past 16 weeks.
Mori K, Inatomi S, Ouchi K, et al. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-372.
Docherty S, Doughty FL, Smith EF. The acute and chronic effects of lion’s mane mushroom supplementation on cognitive function, stress and mood in young adults: a double-blind, parallel groups, pilot study. Nutrients. 2023;15(22):4842.
Menon A, Jalal A, Arshad Z, et al. Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review. Front Nutr. 2025;12:1641246.
Bjornsson HK, Bjornsson ES, Avula B, et al. Ashwagandha-induced liver injury: a case series from Iceland and the US Drug-Induced Liver Injury Network. Liver Int. 2020;40(4):825-829.
McIntyre D, Nguyen P, Kim Y, et al. Ashwagandha (Withania somnifera)-associated liver injury: a scoping review of clinical characteristics and safety considerations. Cureus. 2026;18(5):e109764.
Fatima K, Malik J, Muskan F, et al. Safety and efficacy of Withania somnifera for anxiety and insomnia: systematic review and meta-analysis. Hum Psychopharmacol. 2024;39(6):e2911.
Cheah KL, Norhayati MN, Husniati Yaacob L, Abdul Rahman R. Effect of Ashwagandha (Withania somnifera) extract on sleep: a systematic review and meta-analysis. PLoS One. 2021;16(9):e0257843.
Kumar S, Singh R, Gajbhiye N, Dhanani T. Extraction optimisation for phenolic- and withanolide-rich fractions from Withania somnifera roots. J AOAC Int. 2018;101(6):1773-1780.
McCleary BV, Draga A. Measurement of beta-glucan in mushrooms and mycelial products. J AOAC Int. 2016;99(2):364-373.
Bundesinstitut fuer Risikobewertung. Ashwagandha: food supplements with potential health risks. BfR Communication 39/2024, 10 September 2024.
Food Standards Agency. Call for evidence on the use of ashwagandha in food supplements, closed 2 September 2024; and Regulation (EC) No 1924/2006 as retained in Great Britain law.
DTU National Food Institute, Technical University of Denmark. Risk assessment of ashwagandha (Withania somnifera) in food supplements, 2020; and Danish Veterinary and Food Administration measure prohibiting ashwagandha in food supplements, 2023.
French Agency for Food, Environmental and Occupational Health and Safety (ANSES). Opinion on the risks associated with the consumption of food supplements containing ashwagandha (Withania somnifera).
Vetter J. The mushroom glucans: molecules of high biological and medicinal importance. Foods. 2023;12(5):1009.
Last reviewed 1 October 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.